ReviewJournal of physiology and biochemistry2026
The regulatory effects of extracellular vesicles derived from adipose stem cells on tumor biological activity.
Review in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The field of malignant tumor diagnosis and treatment urgently requires innovative research perspectives to overcome the existing limitations. Extracellular vesicles (EVs) are crucial mediators of intercellular communication, offering novel avenues for regulating tumors. Among these, extracellular vesicles derived from adipose-derived stem cells (ADSC-EVs) have garnered significant attention because of their exceptional stability, safety profile, and ease of storage and transportation. Here, we first elucidate the biological foundation of ADSC-EVs, delineating their biogenesis pathway characterized by the "early endosome-multivesicular body-extracellular release" process, and highlight the heterogeneity of their molecular cargo. This cargo includes 148 regulatory microRNAs (such as the let-7 family and miR-122), 1,466 functional proteins, and various lipid molecules, thereby underpinning its multifunctional regulatory potential. Mechanistically, the dual role of ADSC-EVs is emphasized: on one hand, they can activate signaling pathways, such as PI3K/AKT, or modulate metabolic reprogramming to promote tumor proliferation; on the other hand, they exert tumor-suppressive effects by delivering specific microRNAs (e.g., miR-503-3p) and remodeling the tumor immune microenvironment to influence tumor progression. From an application standpoint, the tripartite value of ADSC-EVs is underscored: serving as potential biomarkers to assist in tumor diagnosis and classification, enabling targeted delivery of anticancer agents following engineering modifications, and functioning as acellular tools that circumvent the risks associated with conventional stem cell therapies. In summary, this study constructed a comprehensive framework for the application of ADSC-EVs in tumor diagnosis and treatment, providing both theoretical and practical support for overcoming therapeutic bottlenecks and developing precision strategies.
Indexed as
Identifiers
42397518What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.